Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 21Polycystic Ovary Syndrome 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Lung Neoplasms 8Endometrial Neoplasms 7Pancreatic Neoplasms 6Neoplasms 6Glioblastoma 5Rectal Neoplasms 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Insulin Resistance 4Adenocarcinoma of Lung 4Adenocarcinoma 4Uterine Cervical Neoplasms 3Leukoplakia, Oral 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Obesity 2Neoplasm Metastasis 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Hyperandrogenism 2Esophageal Neoplasms 2Erythroplasia 2Endometrial Hyperplasia 2Diabetes Mellitus 2Colonic Neoplasms 2

Interventions

Temozolomide 73Bevacizumab 57Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × Metformin × Clear all
NCT06377696 2025-09-02

Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy

Mayo Clinic

Phase 2 Recruiting
100 enrolled
CNS

Brain Neoplasms

NCT04001725 2019-11-13

OPTIMAL

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
110 enrolled
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Diabetes Mellitus, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡